[go: up one dir, main page]

UA93543C2 - Применение дозированной лекарственной формы, которая содержит оксикодон и налоксон - Google Patents

Применение дозированной лекарственной формы, которая содержит оксикодон и налоксон

Info

Publication number
UA93543C2
UA93543C2 UAA200811581A UAA200811581A UA93543C2 UA 93543 C2 UA93543 C2 UA 93543C2 UA A200811581 A UAA200811581 A UA A200811581A UA A200811581 A UAA200811581 A UA A200811581A UA 93543 C2 UA93543 C2 UA 93543C2
Authority
UA
Ukraine
Prior art keywords
dosage form
naloxone
form containing
containing oxycodone
amount
Prior art date
Application number
UAA200811581A
Other languages
English (en)
Ukrainian (uk)
Inventor
Петра Леендеккер
Михаэль Хопп
Кевин Смит
Original Assignee
Ebpo-Селтик C.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34933990&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA93543(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ebpo-Селтик C.A. filed Critical Ebpo-Селтик C.A.
Publication of UA93543C2 publication Critical patent/UA93543C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
UAA200811581A 2005-02-28 2006-02-28 Применение дозированной лекарственной формы, которая содержит оксикодон и налоксон UA93543C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05004377A EP1695700A1 (en) 2005-02-28 2005-02-28 Dosage form containing oxycodone and naloxone

Publications (1)

Publication Number Publication Date
UA93543C2 true UA93543C2 (ru) 2011-02-25

Family

ID=34933990

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200811581A UA93543C2 (ru) 2005-02-28 2006-02-28 Применение дозированной лекарственной формы, которая содержит оксикодон и налоксон

Country Status (26)

Country Link
US (5) US20080145429A1 (ru)
EP (5) EP1695700A1 (ru)
JP (2) JP2008531650A (ru)
KR (1) KR20070107805A (ru)
CN (2) CN104027297A (ru)
AT (1) ATE517611T1 (ru)
AU (2) AU2006217870B2 (ru)
BR (1) BRPI0607975A2 (ru)
CA (3) CA2960011A1 (ru)
CY (1) CY1111967T1 (ru)
DE (2) DE19167974T1 (ru)
DK (2) DK1855657T3 (ru)
ES (1) ES2370409T3 (ru)
FI (1) FI7750U1 (ru)
HR (1) HRP20110775T1 (ru)
IL (2) IL185514A0 (ru)
ME (1) ME01262B (ru)
MX (1) MX2007010494A (ru)
NZ (1) NZ588875A (ru)
PL (1) PL1855657T3 (ru)
PT (1) PT1855657E (ru)
RS (1) RS51984B (ru)
RU (1) RU2428985C2 (ru)
SI (1) SI1855657T1 (ru)
UA (1) UA93543C2 (ru)
WO (1) WO2006089973A2 (ru)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
EP1685839B8 (en) 1997-12-22 2013-06-26 Euro-Celtique S.A. Pharmaceutical oral dosage form comprising a combination of an opioid agonist and opioid antagonist
CA2446550C (en) 2001-05-11 2012-03-06 Endo Pharmaceuticals, Inc. Abuse-resistant controlled-release opioid dosage form
US7056500B2 (en) 2001-10-18 2006-06-06 Nektar Therapeutics Al, Corporation Polymer conjugates of opioid antagonists
ES2627298T3 (es) 2002-04-05 2017-07-27 Mundipharma Pharmaceuticals S.L. Preparación farmacéutica que contiene oxicodona y naloxona
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
EP1604666A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
EP1604667A1 (en) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the restless leg syndrome
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
BRPI0606339A2 (pt) * 2005-01-28 2009-06-16 Euro Celtique Sa formas farmacêuticas resistentes a álcool
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
EP1695700A1 (en) 2005-02-28 2006-08-30 Euro-Celtique S.A. Dosage form containing oxycodone and naloxone
DE202006018609U1 (de) * 2006-08-29 2007-05-16 Euro-Celtique S.A. Verwendung von Opioidformulierungen in nadellosen Vorrichtungen zur Medikamentenverabreichung
BRPI0718554A2 (pt) * 2006-11-07 2013-11-19 Nektar Therapeutics Al Corp Formas de dosagem e co-admimstração de um agonista opióide e um antagonista opióide
US20090004231A1 (en) 2007-06-30 2009-01-01 Popp Shane M Pharmaceutical dosage forms fabricated with nanomaterials for quality monitoring
EP2042176A1 (en) * 2007-09-26 2009-04-01 Euro-Celtique S.A. Use of a combination of an opioid agonist and an opioid antagonist for the treatment of Crohn's disease
WO2009076764A1 (en) 2007-12-17 2009-06-25 Labopharm Inc. Misuse preventative, controlled release formulation
MX2010008138A (es) 2008-01-25 2010-08-10 Gruenenthal Gmbh Forma de dosis farmaceutica.
TWI524904B (zh) 2008-05-09 2016-03-11 歌林達股份有限公司 製備醫藥用固體劑型，尤指錠劑之方法，及製備固體劑型，尤指錠劑之前驅物之方法
PT2317991T (pt) * 2008-07-07 2017-08-03 Euro Celtique Sa Utilização de antagonistas de opióides para tratar a retenção urinária
ES2509497T3 (es) 2008-12-16 2014-10-17 Paladin Labs Inc. Formulación de liberación controlada para evitar un uso indebido
RS58240B1 (sr) * 2009-03-10 2019-03-29 Euro Celtique Sa Farmaceutske kombinacije sa trenutnim oslobađanjem koje obuhvataju oksikodon i nalokson
CA2765971C (en) 2009-07-22 2017-08-22 Gruenenthal Gmbh Hot-melt extruded controlled release dosage form
EP2456425B1 (en) 2009-07-22 2015-10-21 Grünenthal GmbH Tamper-resistant dosage form for oxidation-sensitive opioids
US8475832B2 (en) 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions
US9579285B2 (en) 2010-02-03 2017-02-28 Gruenenthal Gmbh Preparation of a powdery pharmaceutical composition by means of an extruder
US9993433B2 (en) 2010-05-10 2018-06-12 Euro-Celtique S.A. Manufacturing of active-free granules and tablets comprising the same
ES2408343B2 (es) * 2010-05-10 2014-07-17 Euro-Celtique, Sa Composiciones farmacéuticas que comprenden hidromorfona y naloxona
MX344846B (es) 2010-05-10 2017-01-10 Euro-Celtique S A * Combinacion de granulos cargados activos con activos adicionales.
PE20131101A1 (es) * 2010-08-13 2013-09-23 Euro Celtique Sa Formulaciones estables al almacenamiento de oxicodona y naloxona
EP2611426B1 (en) 2010-09-02 2014-06-25 Grünenthal GmbH Tamper resistant dosage form comprising inorganic salt
KR20130137627A (ko) 2010-09-02 2013-12-17 그뤼넨탈 게엠베하 음이온성 중합체를 포함하는 내변조성 투여형
MY162895A (en) * 2010-12-28 2017-07-31 Euro Celtique Sa A combination of an opioid agonist and an opioid antagonist in the treatment of parkinson's disease
KR20140053159A (ko) 2011-07-29 2014-05-07 그뤼넨탈 게엠베하 즉시 약물 방출을 제공하는 탬퍼-저항성 정제
CN103857386A (zh) 2011-07-29 2014-06-11 格吕伦塔尔有限公司 提供药物立即释放的抗破碎片剂
EP2819656A1 (en) 2012-02-28 2015-01-07 Grünenthal GmbH Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
HK1206978A1 (en) 2012-04-17 2016-01-22 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
PT2838512T (pt) 2012-04-18 2018-11-09 Gruenenthal Gmbh Forma farmacêutica resistente à adulteração e resistente à libertação inesperada de alta quantidade (dose-dumping)
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
AU2014273227B2 (en) 2013-05-29 2019-08-15 Grunenthal Gmbh Tamper-resistant dosage form containing one or more particles
AU2014273226B2 (en) 2013-05-29 2019-06-27 Grunenthal Gmbh Tamper resistant dosage form with bimodal release profile
EP3019157A1 (en) 2013-07-12 2016-05-18 Grünenthal GmbH Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
WO2015011189A1 (en) 2013-07-23 2015-01-29 Euro-Celtique S.A. A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
EP3068397A1 (en) 2013-11-13 2016-09-21 Euro-Celtique S.A. Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
CN105934241B (zh) 2013-11-26 2020-06-05 格吕伦塔尔有限公司 通过低温研磨制备粉末状药物组合物
US9192570B2 (en) 2013-12-20 2015-11-24 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
US9561177B2 (en) 2014-03-14 2017-02-07 Adapt Pharma Limited Nasal drug products and methods of their use
US9480644B2 (en) 2014-03-14 2016-11-01 Opiant Pharmaceuticals, Inc. Nasal drug products and methods of their use
US10085937B2 (en) 2014-03-14 2018-10-02 Adapt Pharma Limited Nasal drug products and methods of their use
CN106163499A (zh) 2014-03-14 2016-11-23 欧皮安特制药有限公司 鼻用药物产品及其使用方法
CN106572980A (zh) 2014-05-12 2017-04-19 格吕伦塔尔有限公司 包含他喷他多的防篡改即释胶囊制剂
MX2016015417A (es) 2014-05-26 2017-02-22 Gruenenthal Gmbh Multiparticulas protegidas contra vertido de dosis etanolico.
WO2016016431A1 (en) * 2014-08-01 2016-02-04 Krka, D.D., Novo Mesto Pharmaceutical formulation comprising an opioid agonist and an opioid antagonist prepared by melt granulation using lipid esters
US9849124B2 (en) 2014-10-17 2017-12-26 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
US20160256451A1 (en) * 2015-03-06 2016-09-08 Develco Pharma Schweiz Ag Dosage of naloxone
US20160256453A1 (en) * 2015-03-06 2016-09-08 Develco Pharma Schweiz Ag Opioid receptor antagonist for use in treating patients with severe constipation induced by high opiate dosage regimen
US20160310429A1 (en) 2015-04-24 2016-10-27 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
WO2016193456A2 (en) * 2015-06-03 2016-12-08 Develco Pharma Schweiz Ag Opioid receptor antagonist for use in treating patients with severe constipation
AU2016319203A1 (en) 2015-09-10 2018-02-22 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
US9943513B1 (en) 2015-10-07 2018-04-17 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
AU2018291397A1 (en) 2017-06-30 2020-01-16 Purdue Pharma L.P. Method of treatment and dosage forms thereof
US12475984B2 (en) * 2019-08-05 2025-11-18 Rxassurance Corporation Techniques for providing interactive clinical decision support for drug dosage reduction
US20240131022A1 (en) * 2022-03-11 2024-04-25 John Abernethy Opioid overdose reversal mixtures

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3173876A (en) * 1960-05-27 1965-03-16 John C Zobrist Cleaning methods and compositions
NL271831A (ru) * 1960-11-29
US3276586A (en) * 1963-08-30 1966-10-04 Rosaen Filter Co Indicating means for fluid filters
NL6714885A (ru) * 1967-11-02 1969-05-06
US3541006A (en) * 1968-07-03 1970-11-17 Amicon Corp Ultrafiltration process
US3773955A (en) 1970-08-03 1973-11-20 Bristol Myers Co Analgetic compositions
FR2183546B1 (ru) * 1972-05-10 1975-06-20 Servier Lab
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3916889A (en) * 1973-09-28 1975-11-04 Sandoz Ag Patient ventilator apparatus
US3966940A (en) * 1973-11-09 1976-06-29 Bristol-Myers Company Analgetic compositions
GB1478759A (en) * 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US3966040A (en) * 1975-03-05 1976-06-29 Hazelwood John E Combined vibratory feeder drive unit, vibratory feeder bowl, and parts separator
US4077407A (en) * 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4126684A (en) * 1976-02-11 1978-11-21 Ciba-Geigy Corporation 4-amino-3-p-halophenylbutyric acids and their derivatives used in the control of narcotic abuse
US4063064A (en) * 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
US4285987A (en) * 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4200098A (en) * 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4457933A (en) 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
GB8332556D0 (en) 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
US4668685A (en) * 1984-07-05 1987-05-26 E.I. Du Pont De Nemours And Company Substituted benzoate ester prodrug derivatives of 3-hydroxymorphinans, which are analgesics or narcotic antagonists
US4769372A (en) * 1986-06-18 1988-09-06 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
US4861598A (en) * 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
DE3812567A1 (de) * 1988-04-15 1989-10-26 Basf Ag Verfahren zur herstellung pharmazeutischer mischungen
EP0352361A1 (en) 1988-07-29 1990-01-31 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
US5236714A (en) * 1988-11-01 1993-08-17 Alza Corporation Abusable substance dosage form having reduced abuse potential
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5656295A (en) * 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5286493A (en) * 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
US5681585A (en) * 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5472712A (en) * 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5273760A (en) * 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5324351A (en) * 1992-08-13 1994-06-28 Euroceltique Aqueous dispersions of zein and preparation thereof
IL119660A (en) * 1993-05-10 2002-09-12 Euro Celtique Sa Controlled release formulation comprising tramadol
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
DE4325465B4 (de) * 1993-07-29 2004-03-04 Zenz, Michael, Prof. Dr.med. Orales pharmazeutisches Präparat für die Schmerztherapie
US5411745A (en) * 1994-05-25 1995-05-02 Euro-Celtique, S.A. Powder-layered morphine sulfate formulations
US5866154A (en) * 1994-10-07 1999-02-02 The Dupont Merck Pharmaceutical Company Stabilized naloxone formulations
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US5865161A (en) * 1995-01-04 1999-02-02 Bruce; Norman R. Baseball pitching device
US20020006964A1 (en) * 1995-05-16 2002-01-17 Young James W. Methods of using and compositions comprising (+) sibutramine optionally in combination with other pharmacologically active compounds
DE19651551C2 (de) * 1996-12-11 2000-02-03 Klinge Co Chem Pharm Fab Opioidantagonisthaltige galenische Formulierung
US6207142B1 (en) * 1997-04-14 2001-03-27 Janssen Pharmaceutica N.V. Compositions containing an antifungal and a cationic agent
EP1009387B1 (en) * 1997-07-02 2006-04-12 Euro-Celtique S.A. Stabilized sustained release tramadol formulations
CA2314896C (en) * 1997-12-22 2005-09-13 Euro-Celtique, S.A. A method of preventing abuse of opioid dosage forms
EP1685839B8 (en) * 1997-12-22 2013-06-26 Euro-Celtique S.A. Pharmaceutical oral dosage form comprising a combination of an opioid agonist and opioid antagonist
IL138522A0 (en) * 1998-03-27 2001-10-31 Upjohn Co Use of cabergoline in the treatment of restless legs syndrome
US20030178031A1 (en) * 1999-05-07 2003-09-25 Du Pen, Inc. Method for cancer pain treatment
WO2000078022A1 (en) * 1999-06-11 2000-12-21 Telstra New Wave Pty Ltd A method of developing an interactive system
US20030118641A1 (en) * 2000-07-27 2003-06-26 Roxane Laboratories, Inc. Abuse-resistant sustained-release opioid formulation
DE19938823A1 (de) * 1999-08-19 2001-02-22 Boehringer Ingelheim Pharma Medikamentöse Behandlung des Restless Leg Syndroms
US6258042B1 (en) 1999-09-17 2001-07-10 James S. Factor Visual analog scale and method of use for the diagnosis and/or treatment of physical pain
GEP20053614B (en) * 2000-02-08 2005-09-26 Euro Celtique Sa Compositions for Oral Administration Containing Opioid Agonist
US6716449B2 (en) * 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
US7223421B2 (en) * 2000-06-30 2007-05-29 Mcneil-Ppc, Inc. Teste masked pharmaceutical particles
AR031152A1 (es) * 2000-10-31 2003-09-10 Upjohn Co Tratamientos nuevos para el sindrome de piernas inquietas
DE60235619D1 (de) * 2001-04-19 2010-04-22 Warner Lambert Co Kondensierte bizyklische oder trizyklische aminosäuren
UA81224C2 (ru) * 2001-05-02 2007-12-25 Euro Celtic S A Дозированная форма оксикодона и ее применение
CA2446550C (en) * 2001-05-11 2012-03-06 Endo Pharmaceuticals, Inc. Abuse-resistant controlled-release opioid dosage form
EP1389092B1 (en) * 2001-05-11 2006-11-15 Endo Pharmaceuticals Inc. Abuse-resistant opioid dosage form
JP4256259B2 (ja) * 2001-07-18 2009-04-22 ユーロ−セルティーク エス．エイ． オキシコドン及びナロキソンの医薬配合物
KR20040060917A (ko) * 2001-08-06 2004-07-06 유로-셀티크 소시에떼 아노뉨 오피오이드 남용을 방지하기 위한 조성물 및 방법
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US7332182B2 (en) * 2001-08-06 2008-02-19 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
PT1414451E (pt) * 2001-08-06 2009-07-31 Euro Celtique Sa Formulações agonistas de opióides com antagonista libertável e sequestrado
WO2003026676A1 (en) * 2001-09-24 2003-04-03 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful for the treatment of restless limb syndrome and periodic limb movement disorder
EP1482835B1 (en) 2002-03-06 2012-09-12 Euro-Celtique S.A. Analog scale for measuring pain
ES2627298T3 (es) 2002-04-05 2017-07-27 Mundipharma Pharmaceuticals S.L. Preparación farmacéutica que contiene oxicodona y naloxona
US20030191147A1 (en) * 2002-04-09 2003-10-09 Barry Sherman Opioid antagonist compositions and dosage forms
US7399488B2 (en) * 2002-07-05 2008-07-15 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opiods and other drugs
TWI347201B (en) * 2003-04-21 2011-08-21 Euro Celtique Sa Pharmaceutical products,uses thereof and methods for preparing the same
US7700626B2 (en) * 2004-06-04 2010-04-20 Adolor Corporation Compositions containing opioid antagonists
EP1604666A1 (en) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
EP1695700A1 (en) 2005-02-28 2006-08-30 Euro-Celtique S.A. Dosage form containing oxycodone and naloxone

Also Published As

Publication number Publication date
DK200700248U3 (da) 2008-02-08
CA2960011A1 (en) 2006-08-31
HK1111604A1 (en) 2008-08-15
EP2962686B1 (en) 2019-04-10
JP2014169303A (ja) 2014-09-18
WO2006089973A3 (en) 2006-12-28
EP1855657A2 (en) 2007-11-21
CY1111967T1 (el) 2015-11-04
ATE517611T1 (de) 2011-08-15
RS51984B (sr) 2012-02-29
FI7750U1 (fi) 2008-01-22
WO2006089973A2 (en) 2006-08-31
MX2007010494A (es) 2008-01-16
US20140031382A1 (en) 2014-01-30
EP2258353A3 (en) 2012-05-09
NZ588875A (en) 2012-02-24
IL185514A0 (en) 2008-01-06
ES2370409T3 (es) 2011-12-15
DE202006020095U1 (de) 2007-11-08
EP1855657B1 (en) 2011-07-27
EP2962686A1 (en) 2016-01-06
AU2009201019A1 (en) 2009-04-02
US20110172259A1 (en) 2011-07-14
US20080145429A1 (en) 2008-06-19
RU2007135991A (ru) 2009-04-10
PL1855657T3 (pl) 2012-03-30
EP3578173A1 (en) 2019-12-11
CA2768075A1 (en) 2006-08-31
JP2008531650A (ja) 2008-08-14
IL196539A0 (en) 2011-07-31
US20180008593A1 (en) 2018-01-11
AU2009201019B2 (en) 2011-05-26
EP3578173B1 (en) 2022-10-26
HRP20110775T1 (hr) 2011-11-30
CA2599156C (en) 2012-05-01
SI1855657T1 (sl) 2011-11-30
PT1855657E (pt) 2011-10-31
RU2428985C2 (ru) 2011-09-20
DK1855657T3 (da) 2011-10-17
KR20070107805A (ko) 2007-11-07
AU2006217870B2 (en) 2008-12-18
ME01262B (me) 2013-06-20
AU2006217870A1 (en) 2006-08-31
DK200700248U1 (da) 2007-12-14
DE19167974T1 (de) 2021-12-30
BRPI0607975A2 (pt) 2009-10-27
EP2258353A2 (en) 2010-12-08
EP1695700A1 (en) 2006-08-30
CA2599156A1 (en) 2006-08-31
FIU20070153U0 (fi) 2007-04-13
US20120225901A1 (en) 2012-09-06
JP6235962B2 (ja) 2017-11-22
CN104027297A (zh) 2014-09-10
CN101128191A (zh) 2008-02-20

Similar Documents

Publication Publication Date Title
UA93543C2 (ru) Применение дозированной лекарственной формы, которая содержит оксикодон и налоксон
TWI365880B (en) Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone and oxycodone hydrochloride composition,pharmaceutical dosage form,sustained release oeal dosage form and pharmaceutically acceptable package having less than 25 pp
WO2007053698A3 (en) Methods of reducing alcohol-induced dose dumping for opioid sustained release oral dosage forms
PT2101740E (pt) Nova composição farmacêutica não susceptível de abuso que compreende opióides
MY157715A (en) Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use
EA200870449A1 (ru) Лечение воспалительных и язвенных заболеваний кишечника опиоидными антагонистами
PH12016501342A1 (en) Intranasal pharmaceutical dosage forms comprising naloxone
ZA200701167B (en) Compositions for delivering highly water soluble drugs
NZ589733A (en) Oral administration of peripherally-acting opioid antagonists
SG158168A1 (en) 5ht2c receptor modulator compositions and methods of use
NZ606123A (en) Use of binders for manufacturing storage stable formulations
WO2005102389A3 (en) Combinations comprising alpha-2-delta ligands and ep4 receptor antagonists
CO6341547A2 (es) Uso de antagonistas opioides para el tratamiento de retencion urinaria
MY154591A (en) Therapeutic compositions comprising a specific endothelin receptor antagonist and a pde5 inhibitor
NZ719087A (en) Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
HRP20110049T2 (hr) Opioidi za liječenje nemirnosti kod donjih ekstremiteta
HRP20100373T4 (hr) Upotreba kombinacije morfina s najmanje jednim opijatnim antagonistom u liječenju ovisnosti o opijatima i u sprječavanju neoralne zloupotrebe opijata kod ovisnika opijatima
UA83152C2 (ru) Твердая фармацевтическая композиция, содержащая донепезила гидрохлорид
TW200734334A (en) Treatment of substance abuse
SI2001456T1 (sl) Uporaba zmesi, ki vsebuje antagonist na opioidnem kapa receptorju za zdravljenje disocialnih bolezni
TW200833338A (en) Compounds for the treatment of sexual dysfunction
TW200505504A (en) Saquinavir mesylate oral dosage form
EP1849460A3 (en) Methods of reducing alcohol-induced dose dumping for opioid sustained release oral dosage forms
ZA200804734B (en) Methods of reducing alcohol-induced dose dumping for opioid sustained release oral dosage forms
SI1589014T1 (sl) Postopek za pripravo derivatov 1,3-dihidro-2h-3-benzazepin-2-ona in uporaba za pripravo ivabradina in farmacevtsko sprejemljivih kislinskih adicijskih soli